DOP2013000306A - Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2. - Google Patents
Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2.Info
- Publication number
- DOP2013000306A DOP2013000306A DO2013000306A DO2013000306A DOP2013000306A DO P2013000306 A DOP2013000306 A DO P2013000306A DO 2013000306 A DO2013000306 A DO 2013000306A DO 2013000306 A DO2013000306 A DO 2013000306A DO P2013000306 A DOP2013000306 A DO P2013000306A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cycloalkyl
- condensed
- tetrahydrochinolines
- modulators
- crth2 receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención proporciona determinadas tetrahidroquinolinas condensadas con cicloalquilo de la Fórmula (I), y sus sales y ésteres farmacéuticamente aceptables, en la que R1, R2, R7, R8, R8a, E, Y, Z, n, u, y t son como se define en el presente documento. La invención también proporciona composiciones farmacéuticas que comprenden tales compuestos y el uso de los compuestos para el tratamiento de enfermedades o afecciones asociadas con la estimulación incontrolada o inapropiada de la función de CRTH2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498345P | 2011-06-17 | 2011-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2013000306A true DOP2013000306A (es) | 2014-06-01 |
Family
ID=47357455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2013000306A DOP2013000306A (es) | 2011-06-17 | 2013-12-17 | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2. |
Country Status (25)
Country | Link |
---|---|
US (2) | US8592383B2 (es) |
EP (1) | EP2720545B1 (es) |
JP (1) | JP5629403B2 (es) |
KR (1) | KR101599157B1 (es) |
CN (1) | CN103763924B (es) |
AR (1) | AR086931A1 (es) |
AU (1) | AU2012271661B8 (es) |
BR (1) | BR112013032557A2 (es) |
CA (1) | CA2838731C (es) |
CL (1) | CL2013003625A1 (es) |
CO (1) | CO6821958A2 (es) |
CR (1) | CR20130670A (es) |
DO (1) | DOP2013000306A (es) |
EA (1) | EA025100B1 (es) |
EC (1) | ECSP14013156A (es) |
ES (1) | ES2613644T3 (es) |
IL (1) | IL229508A0 (es) |
MA (1) | MA35188B1 (es) |
MX (1) | MX2013014900A (es) |
NI (1) | NI201300133A (es) |
PE (1) | PE20140788A1 (es) |
TN (1) | TN2013000471A1 (es) |
TW (1) | TW201302711A (es) |
WO (1) | WO2012174176A1 (es) |
ZA (1) | ZA201308942B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5952829B2 (ja) | 2010-12-23 | 2016-07-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Crth2受容体調節剤としてのキノキサリン類およびアザ−キノキサリン類 |
US9290453B2 (en) | 2010-12-23 | 2016-03-22 | Merck Sharp & Dohme Corp. | Quinolines and aza-quinolines as CRTH2 receptor modulators |
EP2922539B1 (en) | 2012-10-01 | 2020-01-15 | Merck Sharp & Dohme Corp. | Substituted isoquinolines as crth2 receptor modulators |
CN104761437B (zh) * | 2015-03-31 | 2018-06-19 | 上海康鹏化学有限公司 | 一种4-溴-2,6-二氟三氟甲氧基苯的制备方法 |
CN104829556B (zh) * | 2015-05-06 | 2018-01-23 | 南京信息工程大学 | 一种由固体光气和氨基硫脲反应制备2‑羟基‑5‑氨基‑1,3,4‑噻二唑的方法 |
EP3337803B1 (en) | 2015-07-23 | 2022-08-17 | Merck Sharp & Dohme LLC | Genetic markers associated with response to crth2 receptor antagonists |
JP7122499B2 (ja) * | 2016-06-03 | 2022-08-22 | 幸久 村田 | がん転移阻害剤 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
JPH10506608A (ja) | 1994-07-11 | 1998-06-30 | アセナ ニューロサイエンシーズ,インコーポレイテッド | 白血球接着のインヒビター |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
WO1996040781A1 (en) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION |
US6034057A (en) | 1995-07-06 | 2000-03-07 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
US5925527A (en) | 1997-02-04 | 1999-07-20 | Trega Biosciences, Inc. | Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
KR100731566B1 (ko) | 1999-10-14 | 2007-06-22 | 가켄 세야쿠 가부시키가이샤 | 테트라히드로퀴놀린 유도체 |
FR2825092B1 (fr) | 2001-05-23 | 2005-01-14 | Servier Lab | Nouveau derives trycicliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2827206B1 (fr) | 2001-07-10 | 2004-04-02 | Nature Bois Emballages | Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes |
US7534897B2 (en) * | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
WO2004035541A1 (en) | 2002-10-15 | 2004-04-29 | Janssen Pharmaceutica, N.V. | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators |
ES2263015T3 (es) | 2002-10-21 | 2006-12-01 | Warner-Lambert Company Llc | Derivados de tetrahidroquinolina como antagonistas de crth2. |
CA2528774A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
US20050038070A1 (en) | 2003-07-09 | 2005-02-17 | Amgen Inc. | Asthma and allergic inflammation modulators |
AR048528A1 (es) | 2004-04-07 | 2006-05-03 | Millennium Pharm Inc | Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen. |
CA2594280C (en) | 2004-12-27 | 2013-04-23 | Anja Fecher | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
UA90706C2 (ru) * | 2005-02-24 | 2010-05-25 | Милленниум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
EP1915372B1 (en) | 2005-08-12 | 2013-11-20 | Merck Canada Inc. | Indole derivatives as crth2 receptor antagonists |
CA2737460C (en) | 2008-09-22 | 2016-12-20 | Merck Frosst Canada Ltd. | Indole derivatives as crth2 receptor antagonists |
CA2737483A1 (en) | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Indole derivatives as crth2 receptor antagonists |
AU2009295231A1 (en) | 2008-09-22 | 2010-03-25 | Merck Canada Inc. | Azaindole derivatives as CRTH2 receptor antagonists |
UA105039C2 (uk) * | 2009-02-24 | 2014-04-10 | Мерк Шарп Енд Доме Корп. | Похідні індолу як антагоністи рецептора crth2 |
US8927559B2 (en) | 2010-10-11 | 2015-01-06 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as CRTH2 antagonists |
JP5952829B2 (ja) | 2010-12-23 | 2016-07-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Crth2受容体調節剤としてのキノキサリン類およびアザ−キノキサリン類 |
US9290453B2 (en) | 2010-12-23 | 2016-03-22 | Merck Sharp & Dohme Corp. | Quinolines and aza-quinolines as CRTH2 receptor modulators |
-
2012
- 2012-06-14 MX MX2013014900A patent/MX2013014900A/es not_active Application Discontinuation
- 2012-06-14 AU AU2012271661A patent/AU2012271661B8/en not_active Ceased
- 2012-06-14 US US13/523,354 patent/US8592383B2/en active Active
- 2012-06-14 AR ARP120102111A patent/AR086931A1/es not_active Application Discontinuation
- 2012-06-14 BR BR112013032557-7A patent/BR112013032557A2/pt active Search and Examination
- 2012-06-14 WO PCT/US2012/042336 patent/WO2012174176A1/en active Application Filing
- 2012-06-14 CA CA2838731A patent/CA2838731C/en not_active Expired - Fee Related
- 2012-06-14 EP EP12799914.2A patent/EP2720545B1/en active Active
- 2012-06-14 PE PE2013002820A patent/PE20140788A1/es not_active Application Discontinuation
- 2012-06-14 CN CN201280029736.0A patent/CN103763924B/zh not_active Expired - Fee Related
- 2012-06-14 JP JP2014515975A patent/JP5629403B2/ja not_active Expired - Fee Related
- 2012-06-14 US US14/126,579 patent/US20140128367A1/en not_active Abandoned
- 2012-06-14 ES ES12799914.2T patent/ES2613644T3/es active Active
- 2012-06-14 EA EA201490031A patent/EA025100B1/ru not_active IP Right Cessation
- 2012-06-14 KR KR1020147000987A patent/KR101599157B1/ko not_active IP Right Cessation
- 2012-06-15 TW TW101121657A patent/TW201302711A/zh unknown
-
2013
- 2013-11-13 TN TNP2013000471A patent/TN2013000471A1/fr unknown
- 2013-11-19 IL IL229508A patent/IL229508A0/en unknown
- 2013-11-27 ZA ZA2013/08942A patent/ZA201308942B/en unknown
- 2013-12-05 NI NI201300133A patent/NI201300133A/es unknown
- 2013-12-12 CO CO13291233A patent/CO6821958A2/es not_active Application Discontinuation
- 2013-12-17 CR CR20130670A patent/CR20130670A/es unknown
- 2013-12-17 CL CL2013003625A patent/CL2013003625A1/es unknown
- 2013-12-17 MA MA36577A patent/MA35188B1/fr unknown
- 2013-12-17 DO DO2013000306A patent/DOP2013000306A/es unknown
-
2014
- 2014-01-17 EC ECSP14013156 patent/ECSP14013156A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2013000306A (es) | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2. | |
CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
ECSP14013215A (es) | Compuestos novedosos | |
UY35142A (es) | Derivados de triazolopirazinas como inhibidores de brd4 | |
ECSP16061758A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
GT201500190A (es) | Lactamas fusionadas de arilo y heteroarilo | |
NI201500077A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
PE20151067A1 (es) | Inhibidores de autotaxina | |
GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
ECSP15025947A (es) | Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales | |
GT201400196A (es) | Compuestos de heterociclilo | |
CL2012003178A1 (es) | Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
DOP2015000076A (es) | Benzamidas | |
GT201200004A (es) | Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria | |
CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
ECSP16074478A (es) | Compuestos novedosos | |
ECSP15029822A (es) | Derivados de imidazopiridazina como moduladores del receptor gabaa | |
ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
CU24482B1 (es) | Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. |